Related Experiment Videos
[Our initial experience with SMANCS in TAE for liver cancer]
1Dept. of Diagnostic Radiology, Osaka Medical Center for Cancer and Cardiovascular Diseases.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|March 26, 1998
Summary
SMANCS chemoembolization for liver cancer shows moderate survival rates but may impact future liver therapies. Further research is needed to optimize treatment strategies.
Area of Science:
- Oncology
- Interventional Radiology
Context:
- Transarterial chemoembolization (TACE) is a standard treatment for liver cancer.
- SMANCS, a specific chemotherapeutic agent, has been investigated as an alternative to traditional TACE agents like Lipiodol.
- Evaluating SMANCS efficacy and safety is crucial for refining liver cancer treatment protocols.
Purpose:
- To assess the efficacy and adverse reactions of SMANCS in patients with liver cancer undergoing TACE.
- To determine survival rates and potential complications associated with SMANCS treatment.
- To compare SMANCS performance against conventional TACE methods.
Summary:
- A review of 10 liver cancer cases treated with SMANCS via TACE was conducted.
- Inclusion criteria for SMANCS included reduced effectiveness of prior TACE, adequate hepatic artery status, and good liver function.
- One- and 2-year survival rates were 50% and 25%, respectively; 3- and 5-year rates were 40% and 20%.
Impact:
- SMANCS demonstrates a potential role in liver cancer treatment, offering moderate survival benefits.
- While generally safe, SMANCS can lead to arterial changes that may complicate subsequent regional therapies.
- These findings highlight the need for careful patient selection and consideration of long-term treatment implications.